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Abstract In this contribution, we report synthetic strate-
gies towards potential ligands for the study of binding
differences between PhzE, the first enzyme in the biosyn-
thesis of phenazines, and the related enzyme anthranilate
synthase. The ligands were designed with the overriding
goal to develop new antibiotics via downregulation of
phenazine biosynthesis.
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Introduction
Phenazines are redox-active secondary metabolites mainly
produced by bacteria such as Streptomyces and Pseu-
domonas conferring the producer a competitive advantage
over other microorganisms [1, 2]. Amongst other modes of
action, phenazines are able to reduce molecular oxygen for
the generation of reactive oxygen species (ROS) [3], and
facilitate energy generation [4–6], e.g., in biofilms [1]. The
production of these secondary metabolites has been shown
to extend the lifespan of the producing organism markedly,
making the phenazine biosynthesis an attractive strategy
for the development of new antibiotics [1, 2].
Over the last decade, the biosynthesis of phenazines has
been elucidated in considerable detail [1, 7, 8], yet there are
still gaps in understanding. Chorismic acid, an important
intermediate of the shikimate pathway, is the starting
material of the core phenazine biosynthesis. Five enzymes,
namely PhzA/B, PhzD, PhzE, PhzF, and PhzG encoded in
the phz operon, catalyze the transformation of chorismic
acid into 5,10-dihydrophenazine-1,6-dicarboxylic acid
(DHPDC) and 5,10-dihydrophenazine-1-carboxylic acid
(DHPCA). Both compounds are central intermediates in
the biosynthesis of strain-specific phenazines (Scheme 1)
[1, 7].
So far, only ligands for PhzA/B have been developed,
which interfere with the later stage of phenazine biosyn-
thesis [9–11]. However, strategically it would be more
attractive to inhibit the phenazine biosynthesis at the ear-
liest possible stage for effective antibiotic intervention.
Upon inhibition of PhzE, phenazine production would be
disabled leading to a loss of competitive advantage of
phenazine-producing bacteria. Therefore, the synthesis of
potent ligands interfering with PhzE would possess
attractive potential for the development of new antibiotics.
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In the first step of the phenazine biosynthesis, PhzE
transforms chorismic acid into 2-amino-2-deoxyisochoris-
mic acid (ADIC) [12]. The same step is catalyzed by AdsX
in the biosynthesis of tilimycin as well as tilivalline [13],
and putatively by TomD in tomaymycin biosynthesis [14].
Homodimeric PhzE consists of two domains, namely the
GATase domain, where NH3 is produced, and a ‘‘me-
naquinone, siderophore, tryptophan (MST)’’ domain where
the reaction of chorismic acid to ADIC takes place [12].
NH3 is channeled into the MST domain via a tunnel with a
length of 25 A˚. Within the MST domain, the ammonia
reacts at the Si-face of the C-6 of chorismic acid to yield
ADIC. [12]. An enzyme related to PhzE is anthranilate
synthase (AS) [15–17]. In AS, ADIC is converted to
anthranilic acid, whereas in PhzE ADIC is handed over to
PhzD for the synthesis of strain-specific phenazines
(Scheme 2).
This discrepancy is somewhat puzzling, as only three
amino acid residues, namely Ser217, Ser368, and Thr369 that
are present in the first coordination sphere of chorismic
acid in PhzE, differ in AS [12]. It is assumed that the
different mode of action originate either from the time
ADIC resides in the active site or from an altered release
path [12]. In addition, it remains unclear why in crystal-
lization experiments of PhzE benzoate and pyruvate
instead of chorismate or ADIC were found in the active site
of the MST domain [12]. It was hypothesized that the
instability [18] of ADIC could account for this observation
[12]. Our goal is to study binding differences between
PhzE and AS to develop specific PhzE inhibitors as
antibiotics. In this paper, we describe our synthetic efforts
leading to the preparation of two potential ligands of PhzE
via two independent routes, which will help to pursue this
goal. Importantly, we could demonstrate that late-stage
structural modifications are feasible in one of the two
ligand syntheses that will give access to additional ligands
in the future.
Results and discussion
We designed ligands rac-5-(carboxylatomethoxy)cyclo-
hexa-1,3-dienecarboxylate disodium salt (1) and rac-trans-
6-amino-5-(carboxymethoxy)cyclohexa-1,3-dienecar-
boxylic acid TFA salt (2) which are structurally similar to
the products of PhzE and AS enzymes, but should not be
turned over by these enzymes as the labile enol ether
moiety is replaced by a stable alkyl ether group (Fig. 1).
Ligand 1 is based on chorismate as it contains two
carboxylate functionalities and a cyclohexadiene base
structure. Whereas 1 features an arrangement of conjugated
double bonds lacking a hydroxyl functionality in position
C-4, chorismate possesses cross-conjugated double bonds
with a hydroxyl in position C-4. With these alterations,
NH3 attack and the elimination of H2O should be disabled
in 1. In addition, the glycolate side chain in 1 confers
additional stability compared with the pyruvate side chain
in chorismate. Ligand 2 is similar to 1, but features an
additional amino functionality in position C-6 anti to the
glycolate side chain. This variation should increase
Scheme 1 
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stability as anti-elimination of the side chain is hampered.
In addition, 2 bears strong resemblance to ADIC making it
a possible product-type inhibitor of PhzE. As an ether
derivative of DHHA, ligand 2 should also be a putative
PhzD inhibitor that could be resistant to enzymatic ether
cleavage. In our synthetic sequence towards ligand 2, we
could show that late-stage derivatization is possible, thus
allowing the synthesis of a diverse set of ADIC analogues
in the future. In crystallization experiments of PhzE, cho-
rismic acid was found to be converted to benzoate and
pyruvate [12]; however, ligands 1 and 2 may remain
stable in the active site thus allowing the investigation of
binding differences between PhzE and AS.
The synthesis of racemic ligand 1 started with the
preparation of the literature-known rac-methyl 5-hydrox-
ycyclohexa-1,3-diene-1-carboxylate (4), following the
method developed by Brion (Scheme 3) [19].
Alcohol 4 was isolated as an oil that degrades slowly
upon storage at - 20 C, as indicated by TLC. To intro-
duce a glycolate side chain in 4, a Williamson
etherification using NaH at low temperature was performed
to deliver advanced intermediate rac-methyl 5-(2-meth-
oxy-2-oxoethoxy)cyclohexa-1,3-diene-1-carboxylate (5) in
37% yield. The planned hydrolysis of the methyl ester
moieties in 5 proved to be a considerable synthetic chal-
lenge, as 5 is fairly unstable under basic conditions leading
to aromatization even upon treatment with 4.2 eq. TMSOK
[20], which is considered to be a rather mild reagent. In an
effort to avoid aromatization, we used NaOH/H2O and
tested various co-solvents. The best result was obtained
when no co-solvent was used. Gratifyingly, when
2.05 eq. NaOH in H2O was used, a clean
1H NMR of 1
could be recorded. It has to be noted that possible side
products or unreacted starting material could not be
detected, but this may be due to their insolubility in D2O/
H2O. Full characterisation of 1 was not performed as
aromatization occurred upon concentration. Due to its
intrinsic instability 1 will only find limited use as a tool
compound.
For the synthesis of racemic ligand 2, we first followed
the literature-known procedure towards advanced inter-
mediate rac-ethyl trans-6-[(tert-butoxycarbonyl)amino]-5-
hydroxycyclohexa-1,3-diene-1-carboxylate (10) according
to Steel and co-workers [21–24], and only minor modifi-
cations were made (Scheme 4). Dienophile ethyl (E)-3-
nitroprop-2-enoate (7) was prepared in two steps in a
combined yield of 47% [25].
The introduction of the glycolate side chain in 10 using
methylbromoacetate as electrophile required substantial
optimization of reaction conditions. In our initial attempts,
we used Ag2O and DBU as bases, but achieved only minor
product formation. Various alkali carbonates and additives
such as NaI and KI led also to unsatisfactory results.
Scheme 2 
Fig. 1 Ligands for the study of binding differences between PhzE
and AS
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Gratifyingly, when we switched to the stronger base NaH,
product yields were significantly improved. At - 10 C,
side product formation could be reduced to a minimum.
When pursuing this reaction on a 700 mg scale, we
warmed the reaction mixture within 4 h from - 20 to 0 C
and could isolate rac-ethyl trans-6-[(tert-butoxycar-
bonyl)amino]-5-(2-methoxy-2-oxoethoxy)cyclohexa-1,3-
diene-1-carboxylate (11) in 38% yield along with 32% of
recovered starting material. For completion of the synthesis
of inhibitor 2, the remaining protecting groups had to be
removed. The best results were obtained when Boc-re-
moval was performed prior to ester hydrolysis. In the first
step, Boc-removal in 11 was achieved using TFA, followed
by ester hydrolysis using aqueous KOH in THF. Upon re-
acidification with TFA, the desired inhibitor 2 was isolated
in 72% yield as a racemic mixture along with CF3CO2K.
Gratifyingly, 2 was found to be a stable ADIC analogue, as
no degradation was detected after 5 days in D2O, whereas
ADIC has a half-life [18] of only approx. 34 h in Tris
buffer at pH 8.0.
Potential ligands 1 and 2 will give valuable insights into
the binding differences between PhzE and AS. However, it
would be advantageous to have access to various additional
ligands for a structure–activity relationship (SAR) assess-
ment. For this reason, we exploited the synthesis of
potential ligand 2 for the preparation of rac-ethyl 5-(2-
amino-2-oxoethoxy)-6-[(tert-butoxycarbonyl)amino]cyclo-
hexa-1,3-diene-1-carboxylate (12) and rac-ethyl 6-[(tert-
butoxycarbonyl)amino]-5-(2-ethoxy-2-oxoethoxy)cyclo-
hex-1-ene-1-carboxylate (13) to show that late-stage
derivatization is a viable strategy for the synthesis of
additional ligand candidates. Advanced intermediates 12
and 13 could be transformed by standard Boc-deprotection
into ester prodrugs susceptible to intracellular ester
hydrolysis, which should offer advantages over the analo-
gous structures with free carboxylic acids, which might be
too charged to cross bacterial cell walls [26].
For the synthesis of 12, we treated 10 with NaH and
iodoacetamide and could isolate ether derivative 12 in 47%
yield (Scheme 5).
A more advanced probe design led to compound 13, in
which only a single olefin remains, which should make this
compound resistant against degradation via aromatization.
Hydrogenation of 9 using an H-cube flow reactor (1 bar
Scheme 3 
Scheme 4 
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H2, 10% Pd/C, rt, 1 h) furnished rac-ethyl 3-[(tert-bu-
toxycarbonyl)amino]-7-oxabicyclo[2.2.1]heptane-2-car-
boxylate (14) [27] in 99% yield without requiring any
purification step (Scheme 6). For the subsequent base-
mediated opening of bicycle 14, freshly prepared LiHMDS
at - 45 C led only to unsatisfactory conversion (19%
yield of 15 ? 65% 14). With KHMDS and warming from
- 45 to - 25 C, substantial side product formation was
observed via TLC. However, at - 50 C, compound 15
could be obtained in satisfactory 38% yield. For the
introduction of the glycolate side chain, we used the neutral
conditions of Rh2(OAc)4-catalyzed OH-insertion with ethyl
diazoacetate and were able to isolate 13 in 53% yield.
We envisage ligands 1 and 2 to serve as model compounds
in the studies of binding differences between PhzE and AS. In
addition, inhibitory constants will enable a comparison with
known inhibitors of AS [28–30]. Most importantly, we could
show that late-stage derivatization at two points in the syn-
thetic protocol towards 2 is possible, which will allow the
synthesis of additional ligands for a SAR assessment.
Conclusion
In summary, we have presented two independent strategies
towards ligands 1 and 2. Both ligands are aimed to interfere
with phenazine biosynthesis in bacteria at the earliest
possible stage with the overriding goal to develop new
antibiotics. Importantly, we could demonstrate that the
synthetic strategy towards ligand 2 allows to access various
derivatives by branching off at two stages of the synthesis,
enabling the study of structure–activity relationship (SAR).
Notably, the stable ligand 2 is designed to serve as a dual-
inhibitor of both PhzE and PhzD, the first two enzymes in
the biocatalytic cascade towards strain-specific phenazines.
In the future, the biophysical characterization of these
ligands will be performed.
Experimental
Reactions were carried out under air, unless indicated
otherwise. For inert reactions, standard Schlenk techniques
under an inert atmosphere of N2 or Ar and anhydrous
solvents were used. In some cases, different batches of
intermediates were pooled and used for a reaction and 1H
NMR was used to assess conformity. The described nuclear
resonance spectra were acquired with the following
instruments: Bruker AVANCE III with Autosampler:
300.36 MHz 1H NMR, 75.53 MHz 13C NMR; Varian
Unity Inova: 499.91 MHz 1H NMR, 125.69 MHz 13C
NMR, 470.35 MHz 19F NMR; Bruker MSL 300 MHz:
282 MHz 19F NMR. Chemical shifts d are referenced to
residual protonated solvent signals as internal standard
D2O: d = 4.79 ppm (
1H), C6D6: d = 7.16 ppm (
1H),
128.06 ppm (13C), and CDCl3: d = 7.26 ppm (
1H),
77.16 ppm (13C). Signal multiplicities are abbreviated as bs
(broad singlet), d (doublet), dd (doublet of doublet), dt
(doublet of triplet), m (multiplet), s (singlet), t (triplet), and
q (quadruplet). The deuterated solvent, the chemical shifts
d in ppm (parts per million), and the coupling constants J in
Hertz (Hz) are given. Deuterated solvents for nuclear res-
onance spectroscopy were purchased from Eurisotop
(CDCl3, C6D6) and Deutero
 (D2O). Analytical thin-layer
chromatography (TLC) was performed on Merck silica gel
60-F254 plates and spots were visualized by UV-light
(k = 254 and/or 366 nm), or by treatment with cerium
ammonium molybdate solution (CAM: 2.0 g Ce(IV)SO4,
50 g (NH4)2MoO4, 50 cm
3 concentrated H2SO4 in 400 cm
3
water) or KMnO4 solution (3.0 g KMnO4 and 20.0 g
K2CO3 dissolved in 300 cm
3 of a 5% NaOH solution).
Flash column chromatography was performed using silica
gel 60 A˚ (35–70 lm particle size) from Acros Organics at
an air pressure of * 1.5 bar. Analytical HPLC measure-
ments were performed on a Shimadzu Nexera Liquid
Chromatograph. The separation of the analytes was carried
out using a C-18 reversed-phase column of the type
OEtO
NHBoc
OH
10
OEtO
NHBoc
O
12
NH2
O
47 %
1.4 eq. NaH
1.8 eq. ICH2CONH2
THF, -20 °C to 0 °C, 3 h
Scheme 5 
Scheme 6 
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‘‘Poroshell 120 SB-C18, 3.0 9 100 mm, 2.7 lm ‘‘by
Agilent Technologies, and detection was accomplished
with a ‘‘Shimadzu SPD-M20A Prominence Diode Array
Detector’’ at a wavelength of k = 210 nm and with the
mass selective detector ‘‘Shimadzu LCMS-2020 Liquid
Chromatograph Mass Spectrometer’’ in the modes ‘‘ESI
positive’’ and ‘‘ESI negative’’. Two different methods were
used: ‘‘standard-1’’: 0.00–0.50 min 70% water/HCO2H and
30% CH3CN, 0.50–6.50 min linear to 100% CH3CN,
6.50–7.20 min 100% CH3CN, 7.20–7.30 min linear to 30%
CH3CN, 7.30–9.00 min 30% CH3CN; 0.7 cm
3
min-1; 40 C or ‘‘standard-2’’: 0.00–1.50 min 100%
water/HCO2H and 0% CH3CN, 1.50–5.50 min linear to
80% CH3CN, 5.50–6.00 min 80% CH3CN, 6.00–6.05 min
linear to 100% CH3CN, 6.05–6.70 min 100% CH3CN,
6.70–6.80 min linear to 0% CH3CN, 6.80–8.00 min 0%
CH3CN; 0.7 cm
3 min-1; 40 C. High-resolution mass
spectrometry (HRMS): TOF MS EI was performed on a
Waters GCT premier micromass with an electron impact
ionization (EI)-source (70 eV) and samples were injected
via an Agilent Technologies GC 7890A with capillary
column (DB-5MS, 30 m 9 0.25 mm 9 0.25 lm film). FT
ICR–MS ESI was performed on a LTQ FT Ultrainstrument
(Thermo Scientific) with an ESI source and samples were
injected using a syringe pump with a flow of 3 mm3 min-1
(capillary temperature was set to either 200 or to 270 C).
Melting points were determined on a Mel-Temp melting-
point apparatus (Electrothermal). High-pressure hydro-
genation experiments were performed using the H-CubeTM
continuous hydrogenation unit (HC-2.SS) from Thales
Nanotechnology Inc. running with a Knauer Smartline
pump 100 and equipped with a 10 cm3 ceramic pump head.
As hydrogenation catalyst 10% Pd/C catalyst cartridges
were used (Thales Nanotechnology inc., THS01111, 10%
Pd/C CatCartTM). Chemicals were purchased from the
companies ABCR, ACROS Organics, Alfa Aesar, Bren-
ntag, Fisher Scientific, Fluka, Merck, Roth, Sigma-Aldrich
or VWR and were used without further purification, unless
stated otherwise. THF and Et2O were distilled, and stored
over KOH. For inert reactions, CH2Cl2 was dried over
CaH2 and distilled under an argon atmosphere before use.
For inert reactions, THF was dried over sodium and dis-
tilled under an argon atmosphere before use.
rac-5-(Carboxylatomethoxy)cyclohexa-1,3-dienecarboxy-
late disodium salt solution (1, C9H8Na2O5)
A N2-flushed Schlenk flask was charged with 50.0 mg of 5
(0.221 mmol) and 1.04 cm3 H2O and the mixture was
degassed (ultrasound bath) and cooled to 0 C (ice bath).
To the stirred solution, 400 mm3 of a NaOH stock solution
(1.13 M NaOH in H2O) was added and the solution turned
slightly yellow. The solution was stirred 12 min at 0 C
and 18 h at rt, after which an NMR sample was taken. 1H
NMR (300 MHz, CDCl3): d = 6.76 (d, J = 3.2 Hz, 1H),
6.34 (dd, J = 9.5 Hz, 5.6 Hz, 1H), 6.23–6.14 (m, 1H),
4.30–4.19 (m, 2H), 3.88 (s, 2H), 3.34 (s, MeOH), 2.85 (dd,
J = 19.0 Hz, 4.4 Hz, 1H), 2.53 (dd, J = 18.9 Hz, 7.7 Hz,
1H) ppm. Side products or unreacted starting material was
not detected and this is maybe due to insolubility in D2O/
H2O. Full characterisation of 1 was not performed as
aromatization occurred upon concentration.
rac-trans-2-Carboxy-6-(carboxymethoxy)cyclohexa-2,4-
dien-1-ammonium 2,2,2-trifluoroacetate
(2, C11H12F3NO7)
In a one-neck round-bottom flask, 7.5 cm3 trifluoroacetic
acid (98 mmol) was added dropwise within 5 min to a
stirred solution of 149 mg of 11 (418 lmol) in 7.5 cm3
CH2Cl2. After 2 h, complete consumption of the starting
material was observed (reaction monitoring via HPLC) and
the pale yellow solution was concentrated in vacuo. The
resulting solid was dissolved in 4 cm3 THF and treated
with 2.89 cm3 1.74 M KOH solution (5.02 mmol). The
mixture was stirred at rt until complete consumption of the
starting material was observed (reaction monitoring via
HPLC). Subsequently, the solution was diluted with 3 cm3
H2O and washed with Et2O (2 9 2 cm
3). The aqueous
layer was then acidified with 50% trifluoroacetic acid to pH
2 and concentrated in vacuo to afford a mixture of 2 and
potassium trifluoroacetate. The mass concentration of
compound 2 was determined via 1H NMR-spectroscopy
using trimethylamine hydrochloride (d(D2O) = 2.90 ppm)
as an external standard: in an NMR tube 100 mm3 of a
1.81 g dm-3 Me3NHCl solution in D2O was added to a
solution of 23.4 mg of the obtained mixture in D2O using a
250 mm3 Hamilton syringe. The mass concentration was
calculated via integration. Yield: 738 mg (13 wt% mixture
with F3CCO2K, 72%), off-white solid. HPLC–MS (‘‘stan-
dard-2’’): tR = 2.45 min (m/z = 214 ([M ? H]
?),
kmax = 280 nm);
1H NMR (500 MHz, D2O): d = 7.35
(d, J = 5.4 Hz, 1H), 6.52–6.42 (m, 2H), 4.57 (d,
J = 5.7 Hz, 1H), 4.51–4.46 (m, 1H), 4.27 (d,
J = 16.6 Hz, 1H), 4.22 (d, J = 16.7 Hz, 1H) ppm; The
relative stereochemistry was determined via 1H NMR via a
coupling constant comparison with ADIC [31]; 13C NMR
(126 MHz, D2O): d = 175.3, 169.1, 162.9 (q,
J = 35.5 Hz), 136.3, 129.4, 126.2, 123.9, 116.3 (q,
J = 291.7 Hz), 73.5, 66.1, 48.2 ppm; 19F NMR
(470 MHz, D2O): d = - 75.6 (F3CCO2
-) ppm; HRMS
(FTICR MS ESI): m/z calcd for [M ? H]? 214.0710,
found 214.0711.
rac-Methyl 7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylate
(3)
The synthesis was performed in analogy to Ref. [19]. A
flame-dried and argon-flushed Schlenk flask was charged
with 5.10 g ZnI2 (16.0 mmol), 5.60 cm
3 furan
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(77.3 mmol), and 4.78 cm3 methyl acrylate (52.8 mmol).
The mixture was stirred at 40 C for 3 days, after which
150 cm3 EtOAc was added. The organic layer was washed
with 1 M Na2S2O3 solution (1 9 80 cm
3), dried over
Na2SO4, filtered, and concentrated in vacuo. The crude
product was purified via silica gel filtration (cyclohexane to
cyclohexane/EtOAc = 1/1) and 4.88 g (41%) of 3 was
isolated as slightly yellow liquid. Rf = 0.30 (cyclohexane/
EtOAc = 4/1, CAM); 1H NMR (300 MHz, CDCl3; endo/
exo-mixture): d = 6.49–6.13 (m, 2H), 5.21–5.09 (m, 1H),
5.03 (m, 1H), 3.67 (2 s, 3H), 3.17–3.00 (m, 0.3H), 2.42 (m,
0.7 H), 2.13 (m, 1H), 1.65–1.43 (m, 1H) ppm; 13C NMR
(APT, 76 MHz, CDCl3; endo/exo-mixture): d = 174.3,
172.7, 137.2, 134.8, 132.7, 81.0, 79.1, 78.8, 78.1, 52.2,
51.8, 42.8, 42.8, 29.2, 28.6 ppm.
rac-Methyl 5-hydroxycyclohexa-1,3-diene-1-carboxylate
(4)
The synthesis was performed in analogy to Ref. [19]. A
flame-dried and argon-flushed two-neck flask was charged
with 1.28 cm3 hexamethyldisilazane (6.14 mmol) and
35 cm3 anhydrous THF. The mixture was stirred and
cooled to - 78 C (dry ice/acetone) and 2.58 cm3 2.21 M
n-BuLi (5.70 mmol) were slowly added. Subsequently, the
mixture was warmed to 0 C and held at that temperature
for 15 min, after which the mixture was again cooled to -
78 C. Subsequently, 790 mg of 3 (5.12 mmol) dissolved
in 6.5 cm3 anhydrous THF was added over the course of
10 min, after which the mixture was slowly warmed to -
47 C in the cooling bath. After 120 min, the solution was
poured into 200 cm3 saturated NH4Cl solution (pre-cooled
to 0 C). The mixture was extracted with CH2Cl2 (4 9
50 cm3) and the combined organic layers were dried over
Na2SO4, filtered, and concentrated in vacuo. The crude
product was purified via flash column chromatography
(cyclohexane/EtOAc = 3/1) and 309 mg (38%) of 4 was
isolated as colorless oil. Rf = 0.50 (cyclohexane/
EtOAc = 1/1, UV); 1H NMR (300 MHz, CDCl3):
d = 7.14–7.01 (m, 1H), 6.30–6.17 (m, 2H), 4.37 (m, 1H),
3.77 (s, 3H), 2.99–2.84 (ddd, J = 18.8 Hz, 5.1 Hz, 0.8 Hz,
1H), 2.70–2.56 (ddd, J = 18.9 Hz, 7.6 Hz, 2.3 Hz, 1H),
1.74 (s, 1H) ppm; 13C NMR (APT, 76 MHz, CDCl3):
d = 167.6, 133.4, 131.6, 127.1, 124.9, 63.3, 52.0,
31.3 ppm.
rac-Methyl 5-(2-methoxy-2-oxoethoxy)cyclohexa-1,3-di-
ene-1-carboxylate (5, C11H14O5)
A flame-dried and argon-flushed Schlenk flask was charged
with 612 mg of 10 (3.97 mmol) and 20 cm3 anhydrous
THF. The mixture was cooled to - 78 C (dry ice/acetone)
and 463 mg NaH (11.6 mmol, 60% dispersion in mineral
oil) was slowly added. The mixture was stirred at - 78 C
for 30 min, then at - 38 C for 15 min, after which
800 mm3 (8.47 mmol) methylbromoacetate was added.
Within 60 min, the reaction mixture was slowly warmed to
- 21 C in the cooling bath, after which complete
consumption of the starting material was observed (reac-
tion monitoring via TLC) and the solution was poured into
300 cm3 saturated NH4Cl solution (pre-cooled to - 15 C).
The mixture was extracted with EtOAc (4 9 60 cm3) and
the combined organic layers were dried over Na2SO4,
filtered, and concentrated in vacuo. The crude product was
purified via flash column chromatography (cyclohexane/
EtOAc = 5/1) and 329 mg (37%) of 5 was isolated as
colorless oil; Rf = 0.30 (cyclohexane/EtOAc = 3/1,
CAM); 1H NMR (300 MHz, CDCl3): d = 7.12–7.02 (m,
1H), 6.27 (m, 2H), 4.29 (m, 1H), 4.15–3.99 (m, 2H), 3.77,
3.74 (2 s, 6H), 3.04–2.90 (m, 1H), 2.60 (m, 1H) ppm; 13C
NMR (APT, 76 MHz, CDCl3): d = 171.0, 167.3, 131.6,
130.1, 127.5, 126.5, 70.9, 64.9, 52.0, 51.9, 27.8 ppm;
HRMS (TOF MS EI): m/z calcd for [M]? 226.0841, found
226.0846.
Ethyl 2-hydroxy-3-nitropropanoate (6)
The synthesis was performed in analogy to Ref. [25]. A
two-neck round-bottom flask equipped with a drying tube
(CaCl2) was charged with 54 cm
3 ethyl glyoxylate solution
(0.27 mol, ca. 50% solution in toluene), 126 cm3 nitro-
methane (2.33 mol), and 54.0 g aluminum oxide
(0.53 mol, activated, neutral). The mixture was stirred
and heated at reflux temperature for 48 h until complete
consumption of the starting material was observed (reac-
tion monitoring via TLC). The resulting brownish-red
suspension was allowed to cool to rt, filtered through a
glass frit and the filter cake was washed with EtOAc (3 9
100 cm3). The solvent was removed in vacuo to furnish a
brownish-red oil, which was purified via flash column
chromatography (cyclohexane/EtOAc = 2/1 to cyclohex-
ane/EtOAc = 1/2). The resulting brownish-red oil was
crystallized in the fridge overnight and 35.4 g (82%) of 6
was isolated as orange to pale yellow crystals. Rf = 0.26
(cyclohexane/EtOAc = 2/1, CAM); m.p.: 35–37 C; 1H
NMR (300 MHz, CDCl3): d = 4.77 (d, J = 4.1 Hz, 2H),
4.63 (m, 1H), 4.40–4.30 (m, 2H), 3.33 (d, J = 4.1 Hz, 1H),
1.33 (t, J = 7.1 Hz, 3H) ppm; 13C NMR (APT, 76 MHz,
CDCl3): d = 170.8, 76.9, 67.7, 63.3, 14.2 ppm.
Ethyl (E)-3-nitroprop-2-enoate (7)
The synthesis was performed in analogy to Ref. [25]. A
flame-dried and argon-flushed 1000 cm3 three-neck round-
bottom flask equipped with a pressure-equalized dropping
funnel and a gas bubbler was charged with 27.2 g of 6
(167 mmol) and 340 cm3 anhydrous CH2Cl2. The solution
was cooled to - 20 C (dry ice/acetone) and 39 cm3
methanesulfonyl chloride (504 mmol) was added dropwise
within 20 min. Subsequently, 71 cm3 anhydrous triethy-
lamine (509 mmol) was added dropwise within 30 min,
whereupon a reddish-brown suspension was formed. The
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mixture was allowed to warm to rt and was stirred
overnight. After 17 h, complete consumption of the
starting material was observed (reaction monitoring via
TLC). The suspension was poured into 1200 cm3 ice-cold
H2O and stirred for 10 min. The organic layer was
separated and the aqueous layer was extracted with
CH2Cl2 (2x300 cm
3). The combined organic layers were
washed with H2O (3 9 200 cm
3), dried over Na2SO4,
filtered, and concentrated in vacuo to furnish a brownish
oil. The crude product was purified via fractional distilla-
tion (14 cm Vigreux column, 0.72 mbar, 36–50 C) to
furnish impure fractions of product containing different
amounts of methanesulfonyl chloride. Subsequently, a flash
column chromatography (cyclohexane/EtOAc = 19/1) was
performed and 14.0 g (58%) of 7 was isolated as bright
yellow oil with pungent odor. Rf = 0.62 (cyclohexane/
EtOAc = 5/1, KMnO4); b.p.: 48–50 C (0.70 mbar); 1H
NMR (300 MHz, CDCl3): d = 7.67 (d, J = 13.5 Hz, 1H),
7.08 (d, J = 13.5 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 1.34
(t, J = 7.1 Hz, 3H) ppm; 13C NMR (APT, 76 MHz,
CDCl3): d = 162.8, 149.1, 127.8, 62.6, 14.1 ppm.
rac-Ethyl endo-3-nitro-7-oxabicyclo[2.2.1]hepta-5-ene-
exo-2-carboxylate (8)
The synthesis was performed in analogy to Ref. [22]. In a
one-neck round-bottom flask 23.9 cm3 furan (329 mmol)
was added to a stirred and cooled (- 20 C, acetone bath/
cryostat) solution of 23.8 g (164 mmol) of 7 in 90 cm3
chloroform. The flask was covered with aluminum foil to
exclude light and the reaction mixture was stirred at -
20 C for 5 d and then at rt for 2 days (reaction monitoring
via TLC). Subsequently, the orange solution was concen-
trated in vacuo to furnish a yellow solid. The crude product
was purified via flash column chromatography (cyclohex-
ane/EtOAc = 8/1). Fractions containing both
diastereomers were purified via two additional flash
column chromatographies (cyclohexane/EtOAc = 8/1)
and 18.8 g (54%) of 8 was isolated as colorless crystals.
Rf = 0.40 (cyclohexane/EtOAc = 3/1, CAM); m.p.:
49–50 C; 1H NMR (300 MHz, C6D6): d = 5.76 (m,
2H), 5.34 (dd, J = 4.8 Hz, 3.1 Hz, 1H), 4.91 (s, 1H),
4.85 (d, J = 4.7 Hz, 1H), 3.84 (q, J = 7.1 Hz, 2H), 2.93
(d, J = 3.0 Hz, 1H), 0.85 (t, J = 7.1 Hz, 3H) ppm; 13C
NMR (APT, 76 MHz, C6D6): d = 169.6, 138.7, 133.7,
84.7, 83.3, 79.1, 61.7, 49.3, 14.0 ppm.
rac-Ethyl endo-3-[(tert-butoxycarbonyl)amino]-7-oxabicy-
clo[2.2.1]hept-5-ene-exo-2-carboxylate (9)
The synthesis was performed in analogy to Ref. [22]. A
one-neck round-bottom flask equipped with a gas bubbler
was charged with 18.2 g oxanorbornene 8 (85.4 mmol) and
790 cm3 EtOH. The yellow solution was cooled to 0 C
(ice bath) and 120 cm3 concentrated HCl (1.44 mol) was
added, followed by the portion-wise addition of 110.8 g
activated zinc dust (1.69 mol; activation by washing twice
with 1 M HCl, H2O, MeOH and subsequent drying in
vacuo). The gray suspension was stirred at 0 C for 30 min
and then at rt for 18 h (reaction monitoring via TLC).
Subsequently, the suspension was filtered through a pad of
Celite and the filter cake was washed with EtOH (1 9
300 cm3). The filtrate was then transferred into a 2000 cm3
one-neck round-bottom flask equipped with a pressure-
equalizing dropping funnel and a gas bubbler, after which
195 cm3 triethylamine (1.40 mol) was added dropwise.
The resulting colorless suspension was treated with 51.0 g
di-tert-butyl dicarbonate (234 mmol) and stirred at rt for
24 h (reaction monitoring via TLC). Subsequently, the
reaction mixture was concentrated in vacuo to furnish a
pale yellow solid, which was dissolved in EtOAc (1 9
1400 cm3). The organic layer was washed with H2O (1 9
1100 cm3) and the aqueous layer was then back-extracted
with EtOAc (1 9 200 cm3). The combined organic layers
were washed with saturated NaHCO3 solution
(1x450 cm3), dried over Na2SO4, filtered, and concentrated
in vacuo. The crude product was purified via flash column
chromatography (cyclohexane/EtOAc = 3/1 to EtOAc)
and 21.1 g (87%) was isolated as colorless solid.
Rf = 0.29 (cyclohexane/EtOAc = 2/1, CAM); m.p.:
101 C; 1H NMR (300 MHz, CDCl3): d = 6.61 (dd,
J = 5.8 Hz, 1.6 Hz, 1H), 6.47 (dd, J = 5.8 Hz, 1.4 Hz,
1H), 5.13 (s, 1H), 5.07 (bs, 1H), 4.55 (bs, 1H), 4.21 (q,
J = 7.1 Hz, 3H), 2.05 (d, J = 3.5 Hz, 1H), 1.44 (s, 9H),
1.29 (t, J = 7.1 Hz, 3H) ppm; 13C NMR (APT, 76 MHz,
CDCl3): d = 171.9, 155.1, 138.0, 134.6, 82.2, 79.1, 61.4,
53.3, 52.6, 28.5, 14.3 ppm (one 13C-signal could not be
observed).
rac-Ethyl trans-6-[(tert-butoxycarbonyl)amino]-5-hydroxy-
cyclohexa-1,3-diene-1-carboxylate (10)
The synthesis was performed in analogy to Ref. [21]. A
flame-dried and argon-flushed two-neck round-bottom
flask was charged with 4.22 g KHMDS (21.2 mmol) and
68 cm3 anhydrous THF. The solution was cooled to -
45 C (dry ice/acetone) and 1.99 g oxanorbornene 9
(7.01 mmol) dissolved in 30 cm3 anhydrous THF (pre-
cooled to - 45 C in a dry ice/acetone bath) was added via
cannula. The mixture was stirred at - 45 C for 100 min
until complete consumption of the starting material was
observed (reaction monitoring via TLC). Subsequently, the
reaction mixture was poured into a separatory funnel
containing 200 cm3 saturated NH4Cl solution. The aqueous
layer was extracted with EtOAc (3 9 90 cm3). The
combined organic layers were dried over Na2SO4, filtered,
and concentrated in vacuo to furnish a brownish-yellow oil.
The crude product was purified via flash column chro-
matography (cyclohexane/EtOAc = 3/2 to cyclohexane/
EtOAc = 1/1) and 1.37 g (69%) of 10 was isolated as
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colorless solid. Rf = 0.36 (cyclohexane/EtOAc = 2/3,
CAM); m.p.: 96–97 C; 1H NMR (300 MHz, CDCl3):
d = 7.17 (d, J = 4.3 Hz, 1H), 6.27 (m, J = 4.2 Hz, 2H),
4.78 (d, J = 7.7 Hz, 1H), 4.59–4.12 (m, 5H), 2.63 (bs, 1H),
1.44 (s, 9H), 1.30 (t, J = 7.1 Hz, 3H) ppm; 13C NMR
(APT, 76 MHz, CDCl3): 155.6, 133.6, 132.8, 124.7, 68.1,
61.0, 50.4, 28.5, 14.3 ppm (13C-signals of quaternary
carbon atoms could not be observed).
rac-Ethyl trans-6-[(tert-butoxycarbonyl)amino]-5-(2-
methoxy-2-oxoethoxy)cyclohexa-1,3-diene-1-carboxylate
(11, C17H25NO7)
A flame-dried and argon-flushed Schlenk flask was charged
with 705 mg of 10 (2.49 mmol), 32 cm3 anhydrous THF
and the mixture was cooled to - 20 C (dry ice/acetone).
To the stirred, slightly yellow solution 131 mg NaH
(3.28 mmol, 60% dispersion in mineral oil) was added,
whereupon the solution became cloudy. After 15 min,
415 mm3 methyl bromoacetate (4.38 mmol) was added
dropwise to the yellow solution, while the temperature was
kept at - 20 C. The mixture was stirred and allowed to
warm to 0 C within 4 h (reaction monitoring via TLC).
Subsequently, the reaction mixture was poured into a flask
containing 50 cm3 ice-cold saturated NH4Cl solution. The
aqueous layer was extracted with EtOAc (3 9 120 cm3).
The combined organic layers were dried over Na2SO4,
filtered, and concentrated in vacuo to furnish a yellow oil.
The crude product was purified via flash column chro-
matography (cyclohexane/EtOAc = 4/1 to cyclohexane/
EtOAc = 1/2) and 337 mg (38%) of 11 was isolated as
colorless solid. In addition, 240 mg of starting material 3
was recovered. Rf = 0.28 (cyclohexane/EtOAc = 2/1,
CAM); m.p.: 70–71 C; 1H NMR (300 MHz, CDCl3):
d = 7.18 (m, 1H), 6.32 (m, 2H), 4.84 (d, J = 7.3 Hz, 1H),
4.47–4.13 (m, 5H), 4.08 (s, 1H), 3.74 (s, 3H), 1.42 (s, 9H),
1.29 (t, J = 7.1 Hz, 3H) ppm; 13C NMR (76 MHz,
CDCl3): d = 171.2, 165.8, 155.1, 133.7, 130.0, 127.6,
125.8, 80.0, 75.6, 66.2, 61.0, 52.0, 46.2, 28.5, 14.3 ppm (2
peaks are missing); HRMS (TOF MS EI): m/z calcd for
[M]? 355.1626, found 355.1637.
rac-Ethyl 5-(2-amino-2-oxoethoxy)-6-[(tert-butoxycar-
bonyl)amino]cyclohexa-1,3-diene-1-carboxylate
(12, C16H24N2O6)
A flame-dried and argon-flushed Schlenk flask was charged
with 250 mg of 10 (0.886 mmol) and 11 cm3 anhydrous
THF and the mixture was cooled to - 20 C (dry ice/
acetone). To the stirred, slightly yellowish solution 48 mg
NaH (1.20 mmol, 60% dispersion in mineral oil) was
added, whereupon the solution became cloudy. After
15 min, 291 mg iodoacetamide (1.57 mmol) was added
to the yellow solution, while the temperature was kept at -
20 C. The mixture was stirred and allowed to warm up to
0 C within 2 h (reaction monitoring via TLC). The
mixture was stirred for another 30 min at this temperature.
Subsequently, the reaction was poured into 30 cm3 satu-
rated NH4Cl solution and the aqueous layer was extracted
with EtOAc (6 9 30 cm3). The combined organic layers
were dried over Na2SO4, filtered, and concentrated in
vacuo to furnish a sticky yellow gum. The crude product
was purified via flash column chromatography (cyclohex-
ane/EtOAc = 1/4) and 141 mg (47%) of 13 was isolated as
yellowish sticky gum. In addition, 47 mg of the starting
material was recovered. Rf = 0.28 (cyclohexane/
EtOAc = 1/4, CAM); 1H NMR (300 MHz, CDCl3):
d = 7.18 (d, J = 5.5 Hz, 1H), 6.54 (bs, 1H), 6.36 (m,
1H), 6.32–6.19 (m, 1H), 5.73 (bs, 1H), 4.85 (d, J = 6.9 Hz,
1H), 4.42–4.00 (m, 6H), 1.42 (s, 9H), 1.30 (t, J = 7.1 Hz,
3H) ppm. The relative stereochemistry was determined via
1H NMR via a coupling constant comparison with com-
pounds 11 and 2 that have been compared to ADIC [31];
13C NMR (APT, 76 MHz, CDCl3): d = 172.4, 165.6,
155.2, 133.3, 129.1, 128.1, 126.8, 74.9, 67.7, 61.2, 47.1,
28.5, 14.3 ppm (3 peaks are missing); HRMS (TOF MS
EI): m/z calcd for [M]? 340.1634, found 340.1647.
rac-Ethyl 6-[(tert-butoxycarbonyl)amino]-5-(2-ethoxy-2-
oxoethoxy)cyclohex-1-ene-1-carboxylate (13)
A flame-dried and argon-flushed Schlenk flask was charged
with 102.6 mg of 15 (0.360 mmol), 1.0 cm3 absolute
CH2Cl2 and 2.6 mg Rh2(OAc)4 (5.89 lmol). To the stirred
solution 64 mg ethyl diazoacetate (0.557 mmol; caution:
toxic and explosive), dissolved in 3 cm3 absolute CH2Cl2,
was added over 1 h at rt. The solution was stirred for
another 60 min, after which full consumption of the
starting material was observed (reaction monitoring via
TLC). The solution was concentrated in vacuo to furnish a
yellow oil. The crude product was purified via flash column
chromatography (cyclohexane/EtOAc = 3/1) and 70.4 mg
(53%) of 13 was isolated as colorless solid. Rf = 0.20
(cyclohexane/EtOAc = 3/1, CAM); m.p.: 106–107 C; 1H
NMR (300 MHz, CDCl3): d = 7.22 (s, 1H), 4.51 (d, 1H,
J = 6.0 Hz), 4.25–4.10 (m, 6H), 3.77 (s, 1H), 2.44 (m,
1H), 2.19 (dt, J = 20.2 Hz, 5.0 Hz, 1H), 2.03 (m, 1H),
1.66 (d, J = 17.6 Hz, 1H), 1.44 (s, 9 H), 1.27 (2 t,
J = 7.1 Hz, 6H) ppm. The relative stereochemistry was
determined via 1H NMR via a coupling constant compar-
ison with compounds 2 and 11 that have been compared
with ADIC [31]; 13C NMR (76 MHz, CDCl3): d = 170.9,
166.2, 154.9, 144.1, 127.5, 79.8, 77.4, 67.0, 60.9, 60.8,
46.0, 28.5, 21.6, 21.5, 14.3 (2 C) ppm (two peaks are
missing); HRMS (TOF MS EI?): m/z calcd for [M-
C4H9 ? H]
? 315.1313, found 315.1312.
rac-Ethyl 3-[(tert-butoxycarbonyl)amino]-7-oxabicy-
clo[2.2.1]heptane-2-carboxylate (14)
The synthesis was performed in analogy to Ref. [27]. A
colorless 5 mM solution of the substrate was prepared by
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dissolving 999.2 mg of 9 (3.53 mmol) in 70 cm3 MeOH
and transferred into a 150 cm3 beaker. For the reduction
itself a continuous-flow hydrogenation reactor (H-cube)
with a 10% Pd/C catalyst cartridge was used with the
following conditions: 1.0 cm3 min-1, rt, atmospheric
pressure, full H2. The reaction was stopped after multiple
runs (ca. 6 times, 8 h). The product solution was
transferred into a 250 cm3 round-bottom flask and the
solvent was removed in vacuo and 995 mg (99%) of 14
was isolated as colorless solid. Rf = 0.73 (cyclohexane/
EtOAc = 2/3, KMnO4); m.p.: 113–115 C; 1H NMR
(300 MHz, CDCl3): d = 4.72 (m, 2H), 4.25 (d,
J = 4.9 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.15 (d,
J = 4.7 Hz, 1H), 1.92–1.75 (m, 2H), 1.75–1.47 (m, 3H),
1.43 (s, 9H), 1.26 (t, J = 7.1 Hz, 3H) ppm; 13C NMR
(76 MHz, CDCl3): d = 172.2, 155.6, 79.8, 78.5, 77.4,
61.3, 56.2, 55.2, 30.2, 28.4, 22.5, 14.3 ppm (2 peaks are
missing).
rac-Ethyl 6-[(tert-butoxycarbonyl)amino]-5-hydroxycyclo-
hex-1-ene-1-carboxylate (15, C14H23NO7)
A flame-dried and argon-flushed Schlenk flask was charged
with 12 cm3 of absolute THF and 835 mg KHMDS
(4.19 mmol). The solution was cooled to - 50 C (dry
ice/acetone). Subsequently, a solution of 403.5 mg of 14
(1.41 mmol) in 6 cm3 absolute THF was added. The
reaction was stirred for 5 h, when complete consumption of
the starting material was observed (reaction monitoring via
TLC). The solution was poured into 40 cm3 saturated
NH4Cl solution and the aqueous layer was extracted with
EtOAc (3 9 40 cm3). The combined organic layers were
dried over Na2SO4, filtered, and concentrated in vacuo. The
crude product was purified via flash column chromatogra-
phy (cyclohexane/EtOAc = 10/1 to cyclohexane/
EtOAc = 2/1) and 151 mg (38%) of 15 was isolated as
colorless solid. Rf = 0.31 (cyclohexane/EtOAc = 1/1,
KMnO4); m.p.: 110–112 C; 1H NMR (300 MHz, CDCl3):
d = 7.18 (s, 1H), 4.53 (s, 1H), 4.38 (s, 1H), 4.31–4.10 (m,
2H), 4.05 (s, 1H), 2.62 (s, 1H), 2.51–2.31 (m, 1H),
2.30–2.13 (m, 1H), 2.13–2.11 (m, 1H), 1.89–1.63 (m, 3H),
1.44 (s, 9H), 1.27 (t, J = 7.1 Hz, 3.5H) ppm; 13C NMR
(APT, 76 MHz, CDCl3): d = 166.3, 143.7, 128.0, 69.2,
60.8, 51.0, 28.5, 24.2, 21.8, 14.3 ppm (4 peaks are
missing); HRMS (TOF MS EI): m/z calcd for [M]?
285.1571, found 285.1574.
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